anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
The inventor has a hobby of medical science from an early age, and has researched and developed &#39;a multifunctional Chinese herbal medicine wine&#39; in December 2010. The &#39;multifunctional Chinese herbal medicine wine&#39; is a medical achievement of the inventor achieved by virtue of more than twenty years of painstaking research. A medicated wine is prepared by soaking twenty-six traditional herbal medicines into a wine and performing fermentation. A formula of the medicated wine comprises the following components: pseudo-ginseng, paris polyphylla, wolfberry, baical skullcap root, salviae miltiorrhizae, szechuan lovage rhizome, epipremnum pinnatum, greater calandine herb, Chinese forgetmenot root, kudzuvine root, longhairy antenoron herb, fortune&#39;s drynaria rhizome, hawthorn fruit, manyprickle acanto-panax root, parasitic weeds on craspedolobium root, Chinese yeast powder, common macrocarpium fruit, radix rehmanniae preparata, cramp powder, eucommia bark, abrus cantoniensis hance, malt, mulberry twig leaves, glossy privet fruit, cultivated boehmeria and wild boehmeria. The medicated wine mainly can be used for treating rheumatism (rheumatoid disease), arthritis, hyperosteogeny, cervical hyperplasia, lumbar hyperosteogeny, nasosinusitis, periarthritis of shoulder, lumbar intervertebral disc hernia, stroke, coronary heart disease, Alzheimer&#39;s disease, osteoporosis, hypertension and injuries from falls, and can be used for diminishing inflammation and sterilizing. Over the past two years, the wine is taken by thousands of people to ensure that the multifunctional Chinese herbal medicine wine has very good treatment effects, can be used for treating diseases of patients suffering the diseases, also can be used for removing toxicity and building the body for people without diseases, can ensure that people feel relaxed in the whole body, and cannot cause toxic or side effects.
An automated health benefit processing system. The system includes a database and three processors. The database includes, for each geographic area and for each medical procedures for which a benefit is payable, the benefit payable to an insured if the procedure is prescribed and performed, a list of providers available to perform the designated procedure, and each provider&#39;s charge for performing the designated procedure. The first processor generates a treatment plan concerning the insured that specifies the identity of the insured and the medical procedures to be performed on the insured. The first processor also accesses the database to retrieve the information stored in the database under the medical procedures to be performed and to append this information to the treatment plan. The second processor generates a treatment record specifying the medical procedures actually performed by a provider and the provider&#39;s actual charge therefor. The third processor processes the information in the treatment plan and treatment records to determine amounts payable to the insured and the provider.
The invention discloses a capsule polyurethane drug controlled release body with a temperature control switch. The capsule polyurethane drug controlled release body is prepared by loading the drug by a temperature-sensitive polyurethane capsule pipe. In the application of the capsule polyurethane drug controlled release body, a drug release characteristic with temperature response is expressed; and an &#39;open-close&#39; effect is present. The capsule wall polyurethane molecules are in a rigid crystalline state below the switch temperature, so that diffusion and release of the drug in the controlled release body are blocked; when the temperature rises to higher than the switch temperature, the polyurethane molecules are in a molten state, so that the drug in the body migrates to the capsule wall and the capsule wall drug release outward continuously, with the concentration as a mass ladder force. Besides, the special design of the capsule wall can realize ideal drug diffusion capacity. The invention also discloses a preparation method of the capsule polyurethane drug controlled release body. The temperature-sensitive polyurethane capsule pipe of the drug controlled release body and unsymmetrical structure of the capsule wall design makes the drug controlled release body have fast temperature response speed, good repeatability of the drug release switch, freely adjustable drug release amount, capacity of uniform drug release, no physiological toxicity, so that the drug controlled release body has wide application prospects in clinic local drug treatment.
FIELD: medicine.SUBSTANCE: method is carried out by means of an optic navigation system with an intra-tumour introduction of a labelled colloidal radiopharmaceutical (RP), for which purpose dynamic scintigraphy of axillary, parasternal, supra and sub-clavian lymph nodes is carried out from the side of the mammary gland tumour localisation 3-5 min after RP introduction. It is repeated within 20-30 min with a 5-10 min interval. The moment of appearance of the first RP-accumulating node is identified and regarded as SLN. At the moment of appearance of the scintigraphic SLN image 4-5 markers of labels, used in the registration of the navigation system are applied on the patient&#39;s skin with positioning: the first marker - in the zone of the humeral head, the second - on lin. ax. anterior in such a way that it does not prevent in performing the biopsy but remains accessible for registration before the operation beginning, the third - at the presternum base, the fourth - 3-5 cm below the third one. In case of the fifth marker fixation its position is not rigidly regulated. Simultaneously SLN topography is determined by means of SPECT-CT - emission computed tomography with the following X-ray computed tomography. In case of impossibility to export volume zones of interest on the SPECT-CT images SLN topography is determined relative to adjoining anatomical structures and obtained information is transferred into the optic navigation system for identification and exact SLN detection in the process of performing the biopsy.EFFECT: method makes it possible to identify true SLN, determine its exact topography and carry out its ablation by means of the optic navigation system, avoiding unjustified ablation of lymph nodes of the second and third order.1 dwg, 1 ex
PURPOSE: To obtain the titled stock solution, by adding sugar and a fermentation promotor to a natural food such as vegetable, fruit, etc., fermenting the blend with sending sterilizing air to give an enzyme stock solution, blending this stock solution with a raw material for Chinese orthodox medicine such as a medical food, etc. in a proper ratio, followed by fermentation.  
     CONSTITUTION: Sugar such as granulated sugar, etc. and a fermentation promotor (e.g., a yeast plant, etc.) is added to a natural food such as vegetable (e.g., cucumber, etc.), fruit (kumquat, etc.), seaweed (e.g., WAKAME seaweed, etc.), mushroom (e.g., Cortinellus shiitake, etc.), and the blend is fermented at 20°C for 70W80hr with stirring while sterilizing air is being introduced. The extracted solution of the raw material is collected from the resulted substance, fermented and aged to give an enzyme stock solution. This stock solution is blended with a raw material for Chinese orthodox medicine such as a medical food (e.g., Mallotus japonicus Muell. Arg., Epimedium macranthum Morr. et Dence. var. violaceum Franch, Polygonatum officinale All., etc.) in a weight ratio wherein the amount of the raw material for Chinese orthodox medicine is larger than that of the enzyme stock solution. Sterilizing air is introduced to the resulted blend, which is fermented, and an extracted solution is collected after three hours. The solution is aged for 3W4 months, to give an enzyme stock solution for Chinese orthodox medicine. 
     COPYRIGHT: (C)1982,JPO&amp;Japio
A habit-based method for smoking cessation. Smoking is a broadly based learned habit, and addiction is irrelevant to cessation. No medications or substances are used, and the Method does not require strict abstinence from smoking. Smoking is a habit broadly conditioned to commonly frequented locations in smoker&#39;s environment. Smoker using Cessation Method restricts smoking to previously not frequented, novel locations. Smoking is prohibited elsewhere. Smoking habit is thus gradually extinguished in commonly visited everyday locations. When extinction is complete, smoker avoids the identified previously not frequented smoking locations, and cessation is accomplished. Smoker also exhaustively identifies disadvantages to smoking and advantages to quitting to maintain motivation for cessation. These motives are employed to overwhelm the smoking habit. When smoker smokes in selected novel locations, the only activity allowed is review of disadvantages to smoking. When not smoking, smoker reviews advantages to quitting as a reward for abstinence.
PURPOSE: To obtain an agent for treating hepatitis C, administering one or more kinds of thymosins at a dose necessary for enhancing immunoresponse to mammal singly or in combination with one or more kinds of interferons used at a dose having antiviral effect. CONSTITUTION: This hepatitis C treating agent for mammal is obtained by combining an effective amount of interferon with thymosin in an amount necessary for enhancing immune system. The interferon is preferably α-, β- or γ-interferon, especially preferably interferon α-2b. An interferon produced by a recombinant DNA technique is preferably used as the interferon. An amount of interferon α used is preferably about 1×10&lt;6&gt; to about 10×10&lt;6&gt; unit. The thymosin is preferably thymosin α-1 or thymosin fraction 5. An amount of thymosin is about 1500-1700 μg of thymosin α-1. The thymosin and the interferon simultaneously or separately may be used.
PURPOSE: To obtain the subject 1st agent capable of protecting the hair from the heat from a flatiron when used in flatiron perming and of extraordinarily improving the hair&#39;s touch feeling, by formulating shellac in a system containing both higher alcohol and reducing gent. CONSTITUTION: This 1st agent for permanent wave is used for flatiron perming to make waves on the hair with a hair grooming flatiron, comprising shellac, a higher alcohol and a reducing agent. The shellac is a resin secreted by Coccus lacca, Tachardia lacca, Laccifer lacca, being parasitic on trees as a result of their sucking of sap. The amount of the shellac to be used is pref. 0.001-1wt.% in the 1st agent. The higher alcohol is e.g. lauryl alcohol, myristy alcohol, cetanol, cetostearyl alcohol, and the reducing agent is e.g. thioglycolic acid, a salt thereof, cysteine, acetyl cysteine. This 1st agent is protective for the hair from heat, giving firm waves to the hair without injuring it and also imparting the hair with favorable touch and luster.
There are provided systems and method for prescription eyeglass ordering through a user device interface. A user may input an eyeglass prescription to a server through taking a vision test using a user device application, inputting the specifics of the prescription through the application, or through taking an image of the prescription form. Once the prescription is input into the server, the server may present eyeglass frames to the user through information of the eyeglass frames. The information may include images of the eyeglass frames and may be superimposed on an image of the user to provide an approximate fit of the frames on the user. Additionally, measurements of the eyeglass frames and the user&#39;s head/facial features may be used in order to provide the fit. The user may choose to purchase the frame and may receive the frame having lenses matching the prescription.
FIELD: perfumery industry, particularly, production of nail polish. SUBSTANCE: nail polish contains film-forming substance, plasticizer, solvent and organic luminophors of various colors of luminescence. All components are taken in definite quantitative ratio. The proposed nail polish ensures additional decorative effect - color luminescence in darkened places provided with a source of ultra-violet light. EFFECT: improved consumers&#39; properties. 2 cl
A smart pill organizer device for use in a networked computer system to wirelessly monitor a patient&#39;s adherence to medication doses, sends alerts when missed, and order refills as needed. The device is a container comprising: a tray of removable dose units tagged with a unique identifier assigned to a patient. The tag may comprise a scannable barcode, and the scanner may be part of the device, or kit. The device further comprises computer components and wireless transmitters, and one or more electromagnetic sensors, e.g. positioned beneath the dose units, to detect when a dose is taken, and transmit the information to a remote server comprising a patient database record. When a dose is missed, an alert is sent to one or more third party electronic computing devices (e.g. patient&#39;s, doctor&#39;s, pharmacy, caregiver&#39;s, etc.). The dose units are filled automatedly with a patient&#39;s prescription by a pharmaceutical robotic system.
The present invention relates to the use of lactic acid bacteria capable of adhering to the mucosa of the intestine and especially colonizing it for the prevention of peritonitis. In particular, the present invention relates to the use of such lactic acid bacteria for the prevention of peritonitis caused by cirrhosis of the liver. Specifically, the present invention relates to a method for preventing peritonitis in a patient in need of such prevention. This method includes administering to the patient a lactic acid bacterium that is capable of adhering to the intestine&#39;s mucosa and essentially colonizing it for the preparation of an ingestable carrier. The invention also relates to a peritonitis preventing composition of a lactic acid bacterium that is capable of adhering to the intestine&#39;s mucosa and essentially colonizing it for the preparation of an ingestable carrier. The carrier is preferably a food or pharmaceutical composition.
FIELD: medicine. SUBSTANCE: aqueous solution of methylcellulose heated to 40-50 C is applied on heated preliminary to 40-50 C paper linen. Then mustard powder is sprayed on it, mustard&#39;s expense being removed. The process is followed by pulling linen between shafts heated to 50-60 C and by drying at 50-60 C. Device for manufacturing sinapism has tape-transport mechanism, bunker for aqueous solution of methylcellulose and drying chamber being displaced above it. Air heater for heating paper linen is displaced in front of bunker; vibrating screen, suction fan and rolling shaft are displaced between bunker and drying chamber. EFFECT: improves efficiency of the method. 1 tbl
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a medicinal composition having an enhanced dissolution stability of bazedoxifene.  &lt;P&gt;SOLUTION: The medicinal composition includes bazedoxifene, and antioxidants such as vitamin E, vitamin E TPGS, propyl gallate, citric acid, and BHA/BHT and is substantially free of ascorbic acid. A method of production of the composition is provided. Methods for increasing dissolution stability of bazedoxifene and biological application capability of preparations containing antioxidants are described. A method for reducing interaction among at least either bazedoxifene or hydroxymethyl cellulose, ascorbic acid and at least one kind of one or more than one decomposition products of ascorbic acid is presented.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
Catching cold and diarrhea are familiar and frequently encountered diseases with high incidence of disease particularly for children. It influences health and growth badly. Now, chese two diseases are so prevalent, since there is little drugs to prevent them. The invention provides a medicine for external application, in order to solve or reduce children suffering from being taken an injection or medicine and parent&#39;s annoyance caused by taking medicine for children. The drug is pasted to umbilici point on bellybutton, stimulating the point, provided with showing effect on preventing and curing cold and diarrhea. The prescription and preparing method are as following: the sticky active extract from water solution of red sage root 150-200, frankincense 100-140, myrrh 100-140, astragalus root 150-200 and Angelica 100-170 etc. is mixed with powders of clove 70-100, cinnamon 70-80, white peony root 200-400. Above admixture being mixed evenly, then made into ointment for use.
PURPOSE: To obtain a percutaneous patch preparation capable of stably performing a percutaneous absorption for a long time by containing clebopride or a salt thereof into a sticky gel base material consisting of a water soluble polymer, water and a water holding agent. CONSTITUTION: This percutaneous patch preparation is obtained by blending clebopride or a salt thereof with a sticky gel base material obtained by blending a water soluble polymer (e.g.; polyvinyl alcohol), water and a water holding agent (e.g.; glycerol) as indispensable components and as necessary an ultra high water absorbing polymer, an assistant for the absorption, a surfactant, an antioxidant, a preservative, etc., suitably, containing 0.5-60wt.% water soluble polymer, 20-80wt.% water and 5-60wt.% water holding agent based on the amount of the base material and preferably adjusting at pH4-7, and coating the blended material on a substrate (e.g.; a nonwoven fabric). The concentration of the clebopride car the salt thereof is 100-600μg/cm&lt;2&gt; .
PURPOSE:To obtain a new compound having excellent beautifying effect and preventing and improving effect on chapped skin. CONSTITUTION:An amide derivative of a tranexamic acid of the formula n is 1-7) and a straight-chain aminocarboxylic acid, such as 3-(trans-4&#39;- aminomethyl-1&#39;-cyclohexylcarbonylamino)propionic acid hydrochloride. The compound is obtained by reacting tranexamic acid or its reactive derivative (e.g. acid halide or active ester) with a straight-chain aminocarboxylic acid in a solvent not participating in the reaction at room temperature to the boiling point of the solvent. In the case wherein tranexamic acid is reacted as it is, a condensation agent such as dicyclohexylcarbodiimide is preferably present. An external preparation for skin is mixed with 0.001-20wt.%, preferably 0.01-7wt.% of the compound.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for reinforcing fragrance and persistence of perfume and a reinforcing agent thereof.  &lt;P&gt;SOLUTION: A perfume composition or a product is added with a compound represented by general formula (1). A compounding amount to the perfume composition is 0.01-90 wt.%. A preferable compounding amount to the product is 0.0001-2.0 times (weight ratio) of the perfume composition compounded in the product. In the formula: A is H or an OH group; B is H or a methyl group; and n is an integer of 0-2.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
The fiber-tangled structure useful as a cell settling material, a wound covering, a medical implant, a starting food product and carriers for a pharmaceutical active substance and for the production a depot medicament, comprises fibers made of partially interlaced gelatin material. The thickness of the fibers is 5-100 mu m. The tangled structure has areas, at which two or more fibers are turned into one another without phase boundary. The capillary suction effect of the tangled structure produces a capillary rise of &gt;= 15 respect to pure water in 120 seconds. The fiber-tangled structure useful as a cell settling material, a wound covering, a medical implant, a starting food product and carriers for a pharmaceutical active substance and for the production a depot medicament, comprises fibers made of partially interlaced gelatin material. The thickness of the fibers is 5-100 mu m. The tangled structure has areas, at which two or more fibers are turned to one another without phase boundary. The capillary suction effect of the tangled structure produces a capillary rise of &gt;= 15 respect to pure water in 120 seconds. The water absorbing capacity of the tangled structure is ten-fold or more of its dry weight. The gelatin material of &gt;= 60 wt.% is amorphous. The tangled structure has an initial wettability of = 1 with respect to pure water, a surface energy of = 10 mN/m, a tear resistance of 140-180 g/m 2&gt; in the dry condition of &gt;= 0.15 N/mm 2&gt;, an elongation at tear of &gt;= 200%, and an open porous structure with an air permeability of &gt;= 0.5 l/minute cm 2&gt;. The tangled structure in hydrated condition forms a closed-porous, fibrous gel structure and has fiber fractions with different average fiber thickness. The fibers are produced by a rotor-spinning procedure and a part of the fibers has a twisted structure. The gelatin material has a gelatin of &gt;= 200 bloom. The tangled structure comprises further fibers, which are formed further material different from the gel material. The gel material has a pharmaceutical active substance. Independent claims are included for: (1) a surface material with layers; and (2) a procedure for the production of fiber tangled structure.
NEW MATERIAL:The compound of formulaI[R1 is H or CH3; R2 is CH2, benzene, etc.,; R2&#39; is CH2, benzene, etc.; R3 is group of formula II (n is O or 1); Y is group of formula III; l is same as n]. USE:A raw material for crosslinking agent of polymer. The polymer derived from the compound is coloreless transparent liquid at normal temperature and pressure having water repellency, and is soluble in organic solvents such as benzene, ether, chloroform, etc., and insoluble in water. It has high boiling point, i.e. it is necessary to heat at &gt;=100 deg.C under the vacuum 2-3mm.Hg for the evaporation of the compound. The compound is useful as a dental filler. PROCESS:The compund of formulaIcan be prepared by reacting the perfluorocarboxylic acid halide of formula CF3CF2COX (X is halogen) or formula IV with the unsaturated carboxylic acid ester of formula V preferably in an organic solvent at -78-+100 deg.C.
The title vaccines, which are for the control of respiratory infections caused by bovine Adenovirus, contain as active ingredient a thermosensitive strain of bovine Adenovirus having a &#34;cut off&#34; temp. of 39-40 degrees C. It is prepd. from a pathogenic strain of bovine Adenovirus by contacting the virus and an aq. buffered soln. of HNO2 at room temp. and pH 4.2-5, and isolating by at least one passage in limited dilution through a tissue culture known to permit growth of the Adenovirus, and suitable as a substrate for vaccine prepns. a thermosensitive mutant strain of bovine Adenovirus having a &#34;cut off&#34; temp. of 39-40 degrees C. The HNO2 soln. is pref. buffered with acetate, and the thermosensitive virus strain is pref. bovine Adenovirus 3 &#34;Eunice&#34;. The vaccine is non-pathogenic.
PROBLEM TO BE SOLVED: To obtain the subject composition having excellent cleansing power capable of removing dirt from the bare skin surface and effects each of prevention of skin deterioration, degerming and bacteriostasis of the skin and deodorization, and stably exerting these effects for many hours by including an effective amount of tea extract in a deoxidized pure water. SOLUTION: This composition is obtained by including an effective amount of tea extract such as catechin, preferably at 20 mg/L to 1.0 wt.%, in pure water deoxidized so as to bring the dissolved oxygen concentration thereof in the composition at 25 deg.C and under 1 atmospheric pressure to preferably &lt;=1.0 mg/L. It is preferable to include, in addition, an effective amount of an acidic antioxidative substance such as vitamin C in this composition. The oxidation-reduction potential of this composition is preferably negative. This composition is applied by spraying on the skin in order to e.g. clean the skin, get a refreshing feeling, wipe the hip of a baby.